AzTrials
AzTrials

Retinal DetachmentsiliconeoilNCT05817630

Duration of Silicone Oil Tamponade on Foveal and Parafoveal Thickness in Rhegmatogenous Retinal Detachment

An observational study of Retinal Detachment, run by Dar El Oyoun Hospital at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Our study observes and analyses the influence of the duration of tamponade with silicone oil on the foveal and parafoveal thickness. Read more about this study

Who is it for?
Any age
Conditions the study is for
Retinal Detachment
What is being tested?
Silicone oil Tamponade for Retinal Detachment
How many people
32 participants
Where
1 siteEgypt
Study dates
15 Feb 2023to 5 Apr 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Retrospective Cohort study Retrospective review of records of eyes with Rhegmatogenous Retinal Detachment (RRD, for whom pars plana vitrectomy and silicone oil had been performed, in the period between January 2019 and December 2021.

Who may be able to join

  • • Silicone oil (SO) tamponade ( up to 6 months)
  • Attached retina under SO
  • Attached retina 3 months after Silicone oil Removal (SOR)
  • Normal fellow eye ( no retinal detachment or macular disease)
  • OCT scan performed for the operated eyes (before SOR, and 3 months after SOR), and for the fellow eye (at any time during the study)

Who cannot join

  • • Rhegmatogenous Retinal Detachment (RRD) with other tamponades ( e.g.: Gas, Densiron)
  • SO tamponade less than 3 months, or more than 6 months
  • Recurrent RD under SO
  • Recurrent RD within 3 months after SOR
  • One eyed
  • Vitrectomized fellow eye
Show all 10Show fewer
  • Retinal detachment, or macular disease in the fellow eye.
  • Posterior staphyloma
  • Anisometropia (history, refraction if possible, spectacles prescription)
  • Absence of any of the OCT scans performed for the operated eyes (before SOR, and 3 months after SOR), and for the fellow eye (at any time during the study)

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Kasr alainy faculty of medicine

    Cairo, 12311

Other trials in Egypt

About this study

Official title: Impact of Duration of Silicone Oil Tamponade on Foveal and Parafoveal Thickness in Rhegmatogenous Retinal Detachment: A Retrospective Cohort Study

Our study observes and analyses the influence of the duration of tamponade with silicone oil on the foveal and parafoveal thickness.

Read the detailed description

Retrospective Cohort study Retrospective review of records of eyes with Rhegmatogenous Retinal Detachment (RRD, for whom pars plana vitrectomy and silicone oil had been performed, in the period between January 2019 and December 2021.

After checking inclusion and exclusion criteria; we will enroll all the cases.

We shall observe the duration of silicone oil tamponade, and then divide the cases; accordingly; into 2 groups (Cohort).

  • Group A: 3 months SO Tamponade
  • Group B: 6 months SO Tamponade
Being tested
Silicone oil Tamponade for Retinal Detachment
Medical subject headings
Retinal Detachment

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Silicone oil Tamponade for Retinal DetachmentOther

    eyes with Rhegmatogenous Retinal Detachment (RRD, for whom pars plana vitrectomy and silicone oil had been performed

Study groups in NCT05817630
Study groupRoleWhat they receive
Group AGroup A: 3 months SO Tamponade
Receives: Other: Silicone oil Tamponade for Retinal Detachment
Group BGroup B: 6 months SO Tamponade
Receives: Other: Silicone oil Tamponade for Retinal Detachment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in CFT just before SOR (central foveal thickness)

    Change in CFT just before SOR (from baseline fellow eye) (microns, %) (each group)

    Measured: baseline to time just before silicone oil removal

  2. Change in PFT just before SOR (Parafoveal thickness)

    Change in PFT just before SOR (from baseline fellow eye) (microns, %) (each group)

    Measured: baseline to time just before silicone oil removal

  3. • Change in CFT after SOR

    • Change in CFT after SOR (from baseline fellow eye) (microns, %) (each group)

    Measured: from baseline fellow eye to 1 month after silicone oil removal

  4. • Change in PFT after SOR

    • Change in PFT after SOR (from baseline fellow eye) (microns, %) (each group)

    Measured: from baseline fellow eye to 1 month after silicone oil removal

Secondary outcomes (4)
  1. • Relative Risk of severe CFT Thinning before SOR (between group A and B)

    • Relative Risk of severe CFT Thinning before SOR (between group A and B)

    Measured: baseline to time just before silicone oil removal

  2. • Relative Risk of severe PFT Thinning before SOR (between group A and B

    • Relative Risk of severe PFT Thinning before SOR (between group A and B

    Measured: baseline to time just before silicone oil removal

  3. • Relative Risk of severe CFT Thinning after SOR (between group A and B)

    • Relative Risk of severe CFT Thinning after SOR (between group A and B)

    Measured: from baseline fellow eye to 1 month after silicone oil removal

  4. • Relative Risk of severe PFT Thinning after SOR (between group A and B)

    • Relative Risk of severe PFT Thinning after SOR (between group A and B)

    Measured: from baseline fellow eye to 1 month after silicone oil removal

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Apr 2023
  2. Study start15 Feb 2023
  3. Primary completion1 Apr 2023
  4. Study completion5 Apr 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
32 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05817630
Sponsor's protocol ID
N-19-2023
Acronym
siliconeoil
Status last verified
Apr 2023
First submitted
5 Apr 2023
Last updated
18 Apr 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Ewais WA, Ali LS, Aboalazayem FM. Impact of duration of silicone oil tamponade on foveal and parafoveal thickness in rhegmatogenous retinal detachment: a retrospective cohort study. Int Ophthalmol. 2024 Apr 2;44(1):167. doi: 10.1007/s10792-024-03096-8.

    PubMed 38565753

Questions about this trial

What is this clinical trial studying?

An observational study of Retinal Detachment, run by Dar El Oyoun Hospital at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in CFT just before SOR (central foveal thickness) (time frame: baseline to time just before silicone oil removal). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05817630, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Apr 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in